FOG 001
Alternative Names: Beta-catenin inhibitor - Parabilis Medicines; FOG-001; β-catenin inhibitor - Parabilis Medicines; β-catenin/TCF4 inhibitor - Parabilis MedicinesLatest Information Update: 10 Jun 2025
At a glance
- Originator FogPharma
- Developer Parabilis Medicines
- Class Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action Beta catenin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 30 May 2025 Efficacy and safety data from a phase I/II trial in Solid tumours released by Parabilis Medicines
- 30 May 2025 Pharmacodynamics data from a preclinical studies released by Parabelis Medicines
- 14 Jan 2025 Efficacy and safety data from a phase I/II trial in Solid tumours released by Parabilis Medicines